ERIS

Eris Lifesciences Limited

Branded formulations pharmaceutical company with diabetes and cardiac therapy focus

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

eris.co.in(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹1144.40
Market cap
15,858 Cr
Stock P/E
24.6
P/B
4.07
Dividend yield
0.6%
ROE (FY26)
15.9%
ROCE (FY26)
13.4%
Operating margin (FY26)
26.9%
Debt / equity (FY26)
0.59
OCF / EBITDA (FY26)
48.0%
OCF / EBITDA (3Y)
74.3%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Eris (Eris Lifesciences) sells branded prescription medicines in India, led by diabetes (including insulins and the semaglutide brand Sundae) and cardiac therapies, and also has an injectables and contract manufacturing (CDMO) business.

Company snapshot

34thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 20.7% — the business keeps a healthy share of every rupee it earns.

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales505 Cr486 Cr551 Cr720 Cr739 Cr727 Cr705 Cr773 Cr792 Cr807 Cr757 Cr873 Cr
Operating expenses (approx.)324 Cr311 Cr402 Cr470 Cr477 Cr477 Cr453 Cr496 Cr504 Cr526 Cr483 Cr577 Cr
EBITDA181 Cr176 Cr148 Cr250 Cr262 Cr250 Cr252 Cr277 Cr288 Cr282 Cr274 Cr296 Cr
OPM %35.8%36.1%26.9%34.7%35.5%34.4%35.8%35.8%36.4%34.9%36.2%33.9%
Other income3 Cr4 Cr15 Cr2 Cr7 Cr4 Cr8 Cr3 Cr3 Cr0.02 Cr2 Cr2 Cr
Interest16 Cr18 Cr33 Cr60 Cr59 Cr57 Cr54 Cr49 Cr50 Cr49 Cr46 Cr47 Cr
Depreciation42 Cr46 Cr54 Cr76 Cr80 Cr81 Cr77 Cr71 Cr69 Cr70 Cr70 Cr72 Cr
Profit before tax126 Cr116 Cr77 Cr115 Cr129 Cr116 Cr129 Cr161 Cr173 Cr145 Cr159 Cr179 Cr
Tax %3.1%12.4%-3.9%22.5%25.4%25.2%20.6%22.3%22.1%25.1%-75.1%20.2%
Net profit122 Cr101 Cr80 Cr89 Cr96 Cr87 Cr102 Cr125 Cr134 Cr109 Cr279 Cr143 Cr
EPS (₹)₹9.08₹7.55₹5.22₹6.11₹6.73₹6.15₹6.90₹8.66₹8.82₹7.32₹20.60₹10.28

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales749 Cr856 Cr982 Cr1,074 Cr1,212 Cr1,347 Cr1,685 Cr2,009 Cr2,894 Cr3,129 CrSign in free for the trailing twelve months
Operating expenses (approx.)480 Cr534 Cr637 Cr706 Cr781 Cr862 Cr1,148 Cr1,334 Cr1,876 Cr2,009 CrSign in free for the trailing twelve months
EBITDA269 Cr322 Cr345 Cr368 Cr431 Cr485 Cr537 Cr675 Cr1,017 Cr1,120 CrSign in free for the trailing twelve months
OPM %35.9%37.6%35.1%34.3%35.5%36.0%31.9%33.6%35.2%35.8%Sign in free for the trailing twelve months
Other income25 Cr26 Cr32 Cr15 Cr9 Cr26 Cr11 Cr24 Cr18 Cr8 CrSign in free for the trailing twelve months
Interest1 Cr11 Cr23 Cr2 Cr2 Cr4 Cr26 Cr85 Cr231 Cr193 CrSign in free for the trailing twelve months
Depreciation23 Cr26 Cr36 Cr50 Cr43 Cr65 Cr117 Cr183 Cr315 Cr280 CrSign in free for the trailing twelve months
Profit before tax270 Cr312 Cr317 Cr331 Cr394 Cr442 Cr405 Cr431 Cr489 Cr639 CrSign in free for the trailing twelve months
Tax %8.8%5.5%8.3%10.5%10.0%8.2%7.5%7.9%23.4%-1.4%Sign in free for the trailing twelve months
Net profit247 Cr295 Cr291 Cr297 Cr355 Cr406 Cr374 Cr397 Cr375 Cr648 CrSign in free for the trailing twelve months
EPS (₹)₹17.95₹21.39₹21.15₹21.61₹26.16₹29.89₹28.10₹28.82₹25.85₹45.33Sign in free for the trailing twelve months
Dividend payout %————21.0%20.1%26.7%0.0%26.7%0.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital14 Cr14 Cr14 Cr14 Cr14 Cr14 Cr14 Cr14 Cr14 Cr14 Cr
Reserves553 Cr848 Cr1,137 Cr1,283 Cr1,563 Cr1,895 Cr2,182 Cr2,573 Cr2,841 Cr3,889 Cr
Borrowings0.49 Cr274 Cr0.29 Cr—0.01 Cr45 Cr830 Cr2,735 Cr2,478 Cr2,310 Cr
Other liabilities135 Cr300 Cr385 Cr256 Cr258 Cr319 Cr617 Cr1,092 Cr1,283 Cr1,160 Cr
Total liabilities727 Cr1,460 Cr1,554 Cr1,552 Cr1,835 Cr2,272 Cr3,667 Cr7,049 Cr7,033 Cr7,366 Cr
Fixed assets (net)56 Cr53 Cr55 Cr87 Cr78 Cr168 Cr356 Cr505 Cr662 Cr708 Cr
CWIP0.07 Cr—0.75 Cr0 Cr0 Cr24 Cr21 Cr19 Cr67 Cr171 Cr
Investments303 Cr365 Cr356 Cr78 Cr294 Cr520 Cr37 Cr16 Cr67 Cr62 Cr
Loans & advances——2 Cr0.94 Cr3 Cr23 Cr4 Cr6 Cr6 Cr53 Cr
Inventories56 Cr65 Cr83 Cr69 Cr94 Cr118 Cr131 Cr189 Cr335 Cr437 Cr
Trade receivables49 Cr67 Cr84 Cr157 Cr140 Cr161 Cr293 Cr422 Cr459 Cr680 Cr
Cash & bank2 Cr11 Cr8 Cr67 Cr37 Cr51 Cr56 Cr94 Cr200 Cr55 Cr
Other assets261 Cr899 Cr965 Cr1,092 Cr1,188 Cr1,207 Cr2,769 Cr5,799 Cr5,238 Cr5,199 Cr
Total assets727 Cr1,460 Cr1,554 Cr1,552 Cr1,835 Cr2,272 Cr3,667 Cr7,049 Cr7,033 Cr7,366 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity200 Cr235 Cr223 Cr271 Cr375 Cr378 Cr292 Cr486 Cr1,065 Cr538 Cr
Cash from investing-184 Cr-590 Cr-5 Cr123 Cr-323 Cr-320 Cr-975 Cr-1,828 Cr-80 Cr-369 Cr
Cash from financing-24 Cr363 Cr-221 Cr-335 Cr-82 Cr-45 Cr688 Cr1,380 Cr-881 Cr-314 Cr
Net cash flow-8 Cr8 Cr-3 Cr60 Cr-30 Cr14 Cr5 Cr38 Cr104 Cr-145 Cr
Free cash flow (OCF − Capex)150 Cr210 Cr185 Cr120 Cr350 Cr257 Cr-550 Cr357 Cr910 Cr241 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %45.9%27.8%29.1%25.7%25.1%22.9%14.1%8.7%12.5%13.4%
ROE %41.8%33.3%24.9%22.9%22.5%21.3%17.2%12.2%10.8%15.9%
Debtor days24283153424363775879
Inventory days403506517330346365336388441487
Days payable278702526475376365319551438367
Cash conversion cycle149-16722-92124480-8661199
OCF / EBITDA %74.4%72.9%64.7%73.6%87.2%78.0%54.4%72.0%104.7%48.0%
OCF / EBITDA % (3 years)——70.3%70.4%76.0%79.8%72.0%68.1%82.7%74.3%
Debt / equity0.00090.320.0003—0.00000.020.381.060.870.59
Current ratio2.851.321.902.912.803.141.730.910.910.74
Net debt / EBITDA-0.0069—-0.02-0.18-0.09-0.011.443.912.242.01